TWEET by @CellCentric
Milestone reached: CCS1477 dosing to lymphoma patients now begun, in addition to MM and AML/MDS. Prostate study also continues.... pic.twitter.com/2J7CuXt6VL
TWEET by @CellCentric
Targeting p300/CBP inhibition to treat cancer is being evaluated in patients. The science behind the approach: cellcentric.com/updates/blog-n… pic.twitter.com/TCCi7rKY9Z
TWEET by @CellCentric
Our first blog: the science behind targeting twin proteins p300 and CBP to treat certain cancers: cellcentric.com/updates/blog-n… pic.twitter.com/OQtW3qkBKW
TWEET by @CellCentric
Welcome Carrie! Our operational team continues to expand, as CCS1477 (first in class p300/CBP inhibitor) progresses in clinical trials. pic.twitter.com/T8UWRAYOxZ
TWEET by @CellCentric
Targeting p300/CBP: a novel approach to treating cancer. Inhibiting cancer-driving gene activation, as well as impacting cancer-related signalling pathways. pic.twitter.com/Gx3fDF1yH9
TWEET by @CellCentric
Delighted that Steven Knapper & team are joining our expanding haem clinical programme. CCS1477 first of its kind p300/CBP inhibitor. pic.twitter.com/1Ku3OHP5ah
